Upstream Bio, Inc.
UPBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Valued at $452.8M, UPB is a small-cap name in its sector. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Market Cap
$452.8M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.76
EPS (TTM)
$-2.90
EPS (Fwd)
$-3.02
ROE
-41.8%
ROA
-27.8%
Cash
$294.6M
Total Debt
$1.1M
Free CF
-$90.3M
52W Change
-9.9%
Annual Financials
Cash vs Debt
Upstream Bio, Inc. holds $294.6M in cash against $1.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$90.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -41.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.2M (2022) to $2.9M (2025), reflecting a 135% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Upstream Bio, Inc. and its sector.